Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination

Journal of Immunology

Volumn 161, Issue 8, 1998, Pages 4183-4194

  Lee, Kang Hun ^a   Panelli, Monica C ^a   Kim, Christina J ^a   Riker, Adam I ^a   Bettinotti, Maria P ^a   Roden, Matthew M ^a   Fetsch, Patricia ^a   Abati, Andrea ^a   Rosenberg, Steven A ^a   Marincola, Francesco M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR ANTIGEN G 209 2M; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CASE REPORT; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; MELANOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; VACCINATION;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; BASE SEQUENCE; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; MELANOMA; MOLECULAR SEQUENCE DATA; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 0032531977     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Rosenberg, S. A. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18:175.
2. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347.
3. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961.
4. Rivoltini, L., Y. Kawakami, K. Sakaguchi, S. Southwood, A. Sette, P. F. Robbins, F. M. Marincola, M. Salgaller, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1995. Induction of tumor reactive CTL from peripheral blood and tumor infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154: 2257.
5. Marincola, F. M., L. Rivoltini, M. L. Salgaller, M. Player, and S. A. Rosenberg. 1996. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence for in vivo priming by tumor cells. J. Immunother. 19:266.
6. Salgaller, M. L., A. Afshar, F. M. Marincola, L. Rivoltini, Y. Kawakami, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res. 55:4972.
7. Cormier, J. N., M. L. Salgaller, T. Prevette, K. C. Barracchini, L. Rivoltini, N. P. Restifo, S. A. Rosenberg, and F. M. Marincola. 1997. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am. 3:37.
8. Salgaller, M. L., F. M. Marincola, J. N. Cormier, and S. A. Rosenberg. 1996. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56:4749.
9. Rosenberg, S. A., J. C. Yang, D. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, E. Dufour, L. Schwartzberg, P. Spiess, J. Wunderlich, M. R. Parkhurst, Y. Kawakami, C. Seipp, J. H. Einhorn, and D. White. 1998. Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.
10. Arden, B., S. P. Clark, D. Kabelitz, and T. W. Mak. 1995. Mouse T-cell receptor variable gene segment families. Immunogenetics 42:501.
11. Parkhurst, M. R., M. L. Salgaller, S. Southwood, P. F. Robbins, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201 binding residues. J. Immunol. 157:2539.
12. Rivoltini, L., K. C. Baracchini, V. Viggiano, Y. Kawakami, A. Smith, A. Mixon, N. P. Restifo, S. L. Topalian, T. B. Simonis, S. A. Rosenberg, and F. M. Marincola. 1995. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen specific cytotoxic T lymphocytes. Cancer Res. 55:3149.
13. Wei, M. L., and P. Cresswell. 1992. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 356:443.
14. Bunce, M., C. M. O'Neill, M. C. Barnardo, P. Krausa, M. J. Browning, P. J. Morris, and K. I. Welsh. 1995. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 46:355.
15. Krausa, P., M. Brywka, D. Savage, K. M. Hui, M. Bunce, J. L. Ngai, D. L. Teo, Y. W. Ong, D. Barouch, C. E. Allsop et al. 1995. Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. Tissue Antigens 45:223.
16. Marincola, F. M., Y. M. Hijazi, P. Fetsch, M. L. Salgaller, L. Rivoltini, J. Cormier, T. B. Simonis, P. H. Duray, M. Herlyn, Y. Kawakami, and S. A. Rosenberg. 1996. Analysis of expression of the melanoma associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J. Immunother. 19:192.
17. Brodsky, F. M., and P. Parham. 1982. Monomorphic anti-HLA-A,B,C monoclonal antibodies detecting molecular subunits and combinatorial determinants. J. Immunol. 128:129.
18. Tsujisaki, M., K. Sakaguchi, M. Igarashi, P. Richiardi, F. Perosa, and S. Ferrone. 1988. Fine specificity and idiotype diversity of the murine anti-HLA-A2, A28 monoclonal antibodies CR11-351 and KS1. Transplantation 45:632.
19. Kawakami, Y., J. K. Battles, T. Kobayashi, W. Ennis, X. Wang, J. P. Tupesis, F. M. Marincola, P. F. Robbins, V. J. Hearing, M. A. Gonda, and S. A. Rosenberg. 1997. Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. J. Immunol. Methods 202:13.
20. Kim, C. J., T. Prevette, J. Cormier, W. Overwijk, M. Roden, N. P. Restifo, S. A. Rosenberg, and F. M. Marincola. 1997. Dendritic cells infected with poxviruses encoding MART-1/MelanA sensitize T lymphocytes in vitro. J. Immunother. 20:276.
21. Zimmerman, P. A., M. N. Carrington, and T. B. Nutman. 1993. Exploiting structural differences among heteroduplex molecules to simplify genotyping the DQA1 and DQB1 alleles in human lymphocyte typing. Nucleic Acids Res. 21: 4541.
22. Gervois, N., Y. Guilloux, E. Diez, and F. Jotereau. 1996. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J. Exp. Med. 183:2403.
23. Wolfel, T., A. Van Pel, V. Brichard, J. Schneider, B. Seliger, K. H. Meyer zum Buschenfelde, and T. Boon. 1994. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24: 759.
24. Van der Bruggen, P., J. Bastin, T. Gajewski, P. G. Coulie, P. Boel, C. De Smet, C. Traversari, A. Townsend, and T. Boon. 1994. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 24:3038.
25. Guilloux, Y., S. Lucas, V. G. Brichard, A. Van Pel, C. Viret, E. De Plaen, F. Brasseur, B. Lethe, F. Jotereau, and T. Boon. 1996. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J. Exp. Med. 183:1173.
26. Ikeda, H., B. Lethe, F. Lehmann, N. van Baren, J. F. Baurain, C. De Smet, H. Chambost, M. Vitale, A. Moretta, T. Boon, and P. G. Coulie. 1997. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199.
27. Fuchs, E. J., and P. Matzinger. 1996. Is cancer dangerous to the immune system? Semin. Immunol. 8:271.
28. Speiser, D. E., R. Miranda, A. Zakarian, M. F. Bachmann, K. McKall-Faienza, B. Odermatt, D. Hanahan, R. M. Zinkernagel, and P. S. Ohashi. 1997. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186:645.
29. Pandolfi, F., L. A. Boyle, L. Trentin, J. T. Kurnick, K. J. Isselbacher, and S. Gattoni-Celli. 1991. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition. Cancer Res. 51:3164.
30. Cormier, J. N., Y. M. Hijazi, A. Abati, P. Fetsch, M. Bettinotti, S. M. Steinberg, S. A. Rosenberg, and F. M. Marincola. 1998. Heterogeneous expression of melanoma-associated antigens (MAA) and HLA-A2 in metastatic melanoma in vivo. Int. J. Cancer 75:517.
31. Toes, R. E., R. Offringa, R. J. Blom, C. J. Melief, and W. M. Kast. 1996. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA 93:7855.
32. Cole, D. J., D. P. Weil, P. Shamamian, L. Rivoltini, Y. Kawakami, S. Topalian, C. Jennings, S. Eliyahu, S. A. Rosenberg, and M. I. Nishimura. 1994. Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. [Published erratum appears in 1994 Cancer Res 54:6014.]. Cancer Res. 54:5265.
33. Campos-Lima, P. O., V. Levitsky, M. P. Imreh, R. Gavioli, and M. G. Masucci. 1997. Epitope-dependent selection of highly restricted or diverse T cell receptor repertoires in response to persistent infection by Epstein-Barr virus. J. Exp. Med. 186:83.
34. Dufour, E., G. Carcelain, C. Gaudin, C. Flament, M. F. Avril, and F. Faure. 1997. Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines. J. Immunol. 158:3787.
35. Alexander-Miller, M. A., G. R. Leggatt, A. Sarin, and J. A. Berzofsky. 1996. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med. 184:485.